Yan Zhang

Yan Zhang

Auto-generated profile, based on publicly available information

Yan Zhang

Bristol-Myers Squibb, Pennington, New Jersey

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Antiviral Therapy
Verified
Journal Article
Open access
YZYubing Zhou
Yubing Zhou
YZYan Zhang
Yan Zhang
XYXiaoang Yang
Xiaoang Yang
JZJing Zhao
Jing Zhao
LZLiyun Zheng
Liyun Zheng
JCJunbiao Chang
Junbiao Chang
Background: HBV infection causes major public health problems worldwide. The clinical limitation of current antiviral drugs for HBV, such as lamivudine, is causing rapid emergence of drug-resistant viral strains during prolonged antiviral therapy. Therefore, new antiviral drugs are urgently needed to prevent or delay the selection of drug-resistant HBV mutants. A novel cytidine analogue, FNC (2′-deoxy-2′-β-fluoro-4′-azidocytidine), was recently shown to strongly inhibit human HBV and duck HBV (DHBV) replication in vitro and in vivo, respectively. The present study was designed to evaluate the in vitro antiviral activity of FNC against clinical wild-type and lamivudine-resistant HBV isolates in transiently transfected cells. Methods: HBV DNA was extracted from serum samples collected both before lamivudine therapy and at the time of viral breakthrough and was amplified by PCR. The amplicon was cloned into a novel expression vector, pHY106, which can initiate the intracellular HBV replication cycle after cell transfection. Following transfection of the cloned amplicon into HepG2 cells, a drug susceptibility assay was performed. Quantitative real-time PCR was used for determining the amount of intracellular HBV DNA, and the effective concentration required to reduce HBV replication by 50% (EC 50 ) was calculated. Results: FNC inhibited the replication of both wild-type and lamivudine-resistant HBV clinical isolates in a dose-dependent manner, with mean ±sd EC 50 values of 0.12 ±0.01 μM and 0.27 ±0.01 μM, respectively. Conclusions: FNC is a potential antiviral agent against both wild-type and lamivudine-resistant HBV clinical isolates, and therefore deserves further evaluation for the treatment of HBV infection.

1 January 2019 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Open access
PDF file
XHXinqiang Huang
Xinqiang Huang
HCHong Cai
Hong Cai
RARon Ammar
Ron Ammar
YZYan Zhang
Yan Zhang
YWYihe Wang
Yihe Wang
GJGabor Jarai
Gabor Jarai
Precision-cut liver tissue slice (PCLS) contains all major cell types of the liver parenchyma and preserves the original cell-cell and cell-matrix contacts. It represents a promising ex vivo model to study liver fibrosis and test the anti-fibrotic effect of experimental compounds in a physiologic environment. In this study using RNAquencing we demonstrated that various pathways functionally related to fibrotic mechanisms were dysregulated in PCLSs derived from rats subjected to bile duct ligation. The Alk5 inhibitor SB525334, nintedanib and sorafenib each reversed a subset of genes dysregulated in fibrotic PCLSs and of those genes we identified 608 genes whose expression was reversed by all three compounds. These genes define a molecular signature characterizing many aspects of liver fibrosis pathology and its attenuation in the model. A panel of 12 genes and 4 secreted biomarkers including procollagen I, HA, IGFBP5 and WISP1, were further validated as efficacy endpoints for the evaluation of anti-fibrotic activity of experimental compounds. Finally, we showed that blockade of αV integrins with a small molecule inhibitor attenuated the fibrotic phenotype in the model. Overall, our results suggest that the rat fibrotic PCLS model may represent a valuable system for target validation and to determine the efficacy of experimental compounds.

20 May 2009 in Surgical and Radiologic Anatomy
Verified
Journal Article
Closed access
PDF file
YZYan Zhang
Yan Zhang
ZLZhenping Li
Zhenping Li
SLShuwei Liu
Shuwei Liu
LFLingzhong Fan
Lingzhong Fan
Lei DongLei Dong
Lei Dong
BLBangling Liang
Bangling Liang